{'52WeekChange': -0.45216048,
 'SandP52WeekChange': None,
 'address1': '1601 Trapelo Road',
 'address2': 'Suite 286',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 3.63,
 'askSize': 3000,
 'averageDailyVolume10Day': 1147562,
 'averageVolume': 3521439,
 'averageVolume10days': 1147562,
 'beta': 1.572549,
 'beta3Year': None,
 'bid': 3.55,
 'bidSize': 40000,
 'bookValue': 0.475,
 'category': None,
 'circulatingSupply': None,
 'city': 'Waltham',
 'companyOfficers': [],
 'country': 'United States',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 3.68,
 'dayLow': 3.44,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': -1.938,
 'enterpriseToRevenue': None,
 'enterpriseValue': 102348896,
 'exDividendDate': None,
 'exchange': 'NMS',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fiftyDayAverage': 3.5761428,
 'fiftyTwoWeekHigh': 15.215,
 'fiftyTwoWeekLow': 1.81,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 33774734,
 'forwardEps': -0.94,
 'forwardPE': -3.787234,
 'fromCurrency': None,
 'fullTimeEmployees': 13,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'headSymbol': None,
 'heldPercentInsiders': 0.03813,
 'heldPercentInstitutions': 0.83212,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': None,
 'lastSplitFactor': None,
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/minervaneurosciences.com',
 'longBusinessSummary': 'Minerva Neurosciences, Inc., a clinical-stage '
                        'biopharmaceutical company, focuses on the development '
                        'and commercialization of a portfolio of product '
                        'candidates for the treatment of central nervous '
                        'system diseases. Its lead product candidate is '
                        'roluperidone, which is in Phase III clinical trial, a '
                        'compound for the treatment of schizophrenia. The '
                        'company is also developing seltorexant that has '
                        'completed Phase IIb clinical trial for treating '
                        'insomnia and major depressive disorders; and MIN-301, '
                        'which is in pre-clinical trial, a soluble recombinant '
                        'form of the neuregulin-1b1 protein for the treatment '
                        "of Parkinson's disease. Minerva Neurosciences, Inc. "
                        'has a license agreement with Mitsubishi Tanabe Pharma '
                        'Corporation for the development and commercialization '
                        'of the roluperidone worldwide, excluding Asia; and '
                        'co-development and license agreement with Janssen '
                        'Pharmaceutica, N.V. for the development of '
                        'seltorexant. The company was formerly known as '
                        'Cyrenaic Pharmaceuticals, Inc. and changed its name '
                        'to Minerva Neurosciences, Inc. in 2013. Minerva '
                        'Neurosciences, Inc. was founded in 2007 and is based '
                        'in Waltham, Massachusetts.',
 'longName': 'Minerva Neurosciences, Inc.',
 'market': 'us_market',
 'marketCap': 139620000,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_261133065',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -68507456,
 'nextFiscalYearEnd': 1640908800,
 'open': 3.56,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': None,
 'phone': '617 600 7373',
 'previousClose': 3.55,
 'priceHint': 4,
 'priceToBook': 7.4947367,
 'priceToSalesTrailing12Months': None,
 'profitMargins': 0,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 3.68,
 'regularMarketDayLow': 3.44,
 'regularMarketOpen': 3.56,
 'regularMarketPreviousClose': 3.55,
 'regularMarketPrice': 3.56,
 'regularMarketVolume': 1577614,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 39219100,
 'sharesPercentSharesOut': 0.1785,
 'sharesShort': 7001644,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 3214466,
 'shortName': 'Minerva Neurosciences, Inc',
 'shortPercentOfFloat': 0.2618,
 'shortRatio': 1.56,
 'startDate': None,
 'state': 'MA',
 'strikePrice': None,
 'symbol': 'NERV',
 'threeYearAverageReturn': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -1.754,
 'twoHundredDayAverage': 6.9593525,
 'underlyingExchangeSymbol': None,
 'underlyingSymbol': None,
 'uuid': 'ceeb0642-b36f-3eda-bb3a-75cdc1b13e8a',
 'volume': 1577614,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.minervaneurosciences.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '02451'}